wherein:

$R^1$ is hydrogen or $C_1$-$C_5$ alkyl;

$R^2$ is hydrogen, $C_1$-$C_5$ alkyl or $C_2$-$C_6$ alkenyl;

$R^3$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_3$-$C_{10}$ alkenyl, phenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl or phenyl-substituted $C_1$-$C_3$ alkyl;

A is $OR^4$ or $NR^5R^6$;

B1 cont.

wherein:

$R^4$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_2$-$C_{10}$ alkenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl or phenyl-substituted $C_1$-$C_3$ alkyl;

$R^5$ is hydrogen or $C_1$-$C_3$ alkyl;

$R^6$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_3$-$C_{10}$ alkenyl, cycloalkyl, phenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, $C_5$-$C_8$ cycloalkenyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl, phenyl-substituted $C_1$-$C_3$ alkyl, or $(CH_2)_q$-B; or

$R^5$ and $R^6$ [are each $CH_2$ which] together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

[wherein:]

B is  , CW or $NR^7R^8$;

[wherein:]

$R^7$ is hydrogen or $C_1$-$C_3$ alkyl;

$R^8$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_3$-$C_{10}$ alkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl, phenyl or phenyl-substituted $C_1$-$C_3$ alkyl; or

$R^7$ and $R^8$ [are each $CH_2$ which] together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

W is $OR^9$, $NR^{10}R^{11}$, or OE;

[wherein:]

$R^9$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_2$-$C_{10}$ alkenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl or phenyl-substituted $C_1$-$C_3$ alkyl;

$R^{10}$ is hydrogen or $C_1$-$C_3$ alkyl;

$R^{11}$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_3$-$C_{10}$ alkenyl, phenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, phenyl-substituted $C_1$-$C_3$ alkyl,



or $(CH_2)_mCY$; or

$R^{10}$ and $R^{11}$ [are each $CH_2$ which] together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

E is 
$(CH_2)_mC$-D,  , or $-R^{12}$-
$OCR^{13}$

[wherein:]

$R^{12}$ is $C_1$-$C_3$ alkyl substituted methylene,

$R^{13}$ is $C_1$-$C_{10}$ alkyl;

D is $OR^{14}$ or $NR^{15}R^{16}$;

wherein:

$R^{14}$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_2$-$C_{10}$ alkenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, or $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl or phenyl-substituted $C_1$-$C_3$ alkyl;

$R^{15}$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_3$-$C_{10}$ alkenyl, phenyl, phenyl-substituted $C_1$-$C_3$ alkyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl or $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl; and

$R^{16}$ is hydrogen or $C_1$-$C_3$ alkyl; or

$R^{15}$ and $R^{16}$ [are each $CH_2$ which] together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

Y is $OR^{17}$ or $NR^{18}R^{19}$;

[wherein:]

$R^{17}$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_2$-$C_{10}$ alkenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl, or phenyl-substituted $C_1$-$C_3$ alkyl;

$R^{18}$ is hydrogen or $C_1$-$C_3$ alkyl; and

$R^{19}$ is hydrogen, $C_1$-$C_{10}$ alkyl, $C_3$-$C_{10}$ alkenyl, phenyl, cycloalkyl, $C_5$-$C_8$ cycloalkenyl, cycloalkyl-substituted $C_1$-$C_3$ alkyl, $C_5$-$C_8$ cycloalkenyl-substituted $C_1$-$C_3$ alkyl, or phenyl-substituted $C_1$-$C_3$ alkyl; or

$R^{18}$ and $R^{19}$ [are each $CH_2$ which] together with N form a saturated non aromatic 4- to 6-membered heterocyclic ring;

n is 0-4;

q is 1-4;

m is 1-4;

or a pharmaceutically acceptable salt[s] thereof.

B1 cont.

17. (Amended) A method for [treating] binding a peripheral [effect of an] opioid receptor in a patient which comprises administering to said patient an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

B2

Add Claims 21-40.

B3

21. A method of Claim 16 wherein the compound is one wherein $R^1$ is hydrogen; $R^2$ is $C_1$-$C_3$ alkyl; n = 1 or 2; and $R^3$ is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

22. A method of Claim 21 wherein the compound is one wherein A is $NR^5R^6$ and $R^5$ is hydrogen, $R^6$ is $(CH_2)_q$-B, q is 1 to 3 and B is -C(O)W.

23. A method of Claim 22 wherein the compound is one wherein W is $OR^9$ and $R^9$ is hydrogen, $C_1$-$C_5$ alkyl, phenyl-substituted $C_1$-$C_2$ alkyl, $C_5$-$C_6$ cycloalkyl, or $C_5$-$C_6$ cycloalkyl-substituted $C_1$-$C_3$ alkyl.

24. A method for treating irritable bowel syndrome in a patient comprising administering to the patient an effective amount of a compound of Claim 11.

25. A method of Claim 24 wherein the compound is selected from the group consisting of (3R,4R,S)-Z-$NHCH_2C(O)OCH_2CH(CH_3)_2$, (+)Z-$NHCH_2C(O)OH$, (-)Z-$NHCH_2C(O)OH$, (3R,4R,R)-$ZNHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,S)-$ZNHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,R)-$ZNHCH_2C(O)OCH_2CH(CH_3)_2$, (3R,4R)-$ZNHCH_2C(O)NHCH_2(C_6H_5)$ and (3R,4R)-G-$NH(CH_2)_3C(O)OH$.

26. A method of Claim 18 wherein the compound is one wherein $R^1$ is hydrogen; $R^2$ is $C_1$-$C_3$ alkyl; n = 1 or 2; and $R^3$ is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

27. A method of Claim 26 wherein the compound is one wherein A is $NR^5R^6$ and $R^5$ is hydrogen, $R^6$ is $(CH_2)_q$-B, q is 1 to 3 and B is -C(O)W.

28. A method of Claim 27 wherein the compound is one wherein W is $OR^9$ and $R^9$ is hydrogen, $C_1$-$C_5$ alkyl, phenyl-substituted $C_1$-$C_2$ alkyl, $C_5$-$C_6$ cycloalkyl, or $C_5$-$C_6$ cycloalkyl-substituted $C_1$-$C_3$ alkyl.

29. A method for binding a peripheral opioid receptor in a patient which comprises administering to said patient an effective amount of a compound of Claim 11.

30. A method of Claim 29 wherein the compound is one selected from the group consisting of (3R,4R,S)-Z-$NHCH_2C(O)OCH_2CH(CH_3)_2$, (+)Z-$NHCH_2C(O)OH$, (-)Z-$NHCH_2C(O)OH$, (3R,4R,R)-$ZNHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,S)-$ZNHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,R)-$ZNHCH_2C(O)OCH_2CH(CH_3)_2$, (3R,4R)-$ZNHCH_2C(O)NHCH_2(C_6H_5)$ and (3R,4R)-G-$NH(CH_2)_3C(O)OH$.

31. A method of Claim 19 wherein the compound is one wherein $R^1$ is hydrogen; $R^2$ is $C_1$-$C_3$ alkyl; n = 1 or 2; and $R^3$ is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

32. A method of Claim 31 wherein the compound is one wherein A is $NR^5R^6$ and $R^5$ is hydrogen, $R^6$ is $(CH_2)_q$-B, q is 1 to 3 and B is -C(O)W.

33. A method of Claim 32 wherein the compound is one wherein W is $OR^9$ and $R^9$ is hydrogen, $C_1$-$C_5$ alkyl, phenyl-substituted $C_1$-$C_2$ alkyl, $C_5$-$C_6$ cycloalkyl, or $C_5$-$C_6$ cycloalkyl-substituted $C_1$-$C_3$ alkyl.

34. A method for blocking a mu receptor in a mammal comprising administering to a mammal requiring blocking of a mu receptor a receptor blocking dose of a compound of Claim 11.

35. A method of Claim 34 wherein the compound is one selected from the group consisting of (3R,4R,S)-Z-$NHCH_2C(O)OCH_2CH(CH_3)_2$, (+)Z-$NHCH_2C(O)OH$, (-)Z-$NHCH_2C(O)OH$, (3R,4R,R)-Z$NHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,S)- Z$NHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,R)-Z$NHCH_2C(O)OCH_2CH(CH_3)_2$,, (3R,4R)-Z$NHCH_2C(O)NHCH_2(C_6H_5)$ and (3R,4R)-G-$NH(CH_2)_3C(O)OH$.

36. A method of Claim 20 wherein the compound is one wherein $R^1$ is hydrogen; $R^2$ is $C_1$-$C_3$ alkyl; n = 1 or 2; and $R^3$ is benzyl, phenyl, cyclohexyl, or cyclohexylmethyl.

37. A method of Claim 36 wherein the compound is one wherein A is $NR^5R^6$ and $R^5$ is hydrogen, $R^6$ is $(CH_2)_q$-B, q is 1 to 3 and B is -C(O)W.

38. A method of Claim 37 wherein the comound is one wherein W is $OR^9$ and $R^9$ is hydrogen, $C_1$-$C_5$ alkyl, phenyl-substituted $C_1$-$C_2$ alkyl, $C_5$-$C_6$ cycloalkyl, or $C_5$-$C_6$ cycloalkyl-substituted $C_1$-$C_3$ alkyl.

39. A method for treating idiopathic constipation in a patient comprising administering to the patient an effective amount of a compound of Claim 11.

40. A method of Claim 39 wherein the compound is one selected from the group consisting of (3R,4R,S)-Z-$NHCH_2C(O)OCH_2CH(CH_3)_2$, (+)Z-$NHCH_2C(O)OH$, (-)Z-$NHCH_2C(O)OH$, (3R,4R,R)-Z$NHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,S)- Z$NHCH_2C(O)OCH_2CH(CH_3)_2$, (3S,4S,R)-Z$NHCH_2C(O)OCH_2CH(CH_3)_2$,, (3R,4R)-Z$NHCH_2C(O)NHCH_2(C_6H_5)$ and (3R,4R)-G-$NH(CH_2)_3C(O)OH$.

In the Specification

Page 8, line 16, delete the phrase "substituted methyl" and insert therefor --substituted methylene--.

Page 8, line 17, delete the phrase "hydrogen or $C_1$-$C_4$ alkyl; $R^{11}$ is hydrogen or $C_1$-$C_4$ alkyl; n is 1; and $R_{12}$ is hydrogen."

Page 15, line 12, delete the phrase "$R^{11}$ and $R^{12}$" and insert therefor --$R^{23}$ and $R^{24}$--.